Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Joshua Staley
- Phone Number: 913-588-8548
- Email: jstaley2@kumc.edu
Study Locations
-
-
Kansas
-
Hays, Kansas, United States, 67601
- Recruiting
- Hays Medical Center Dreiling-Schmidt Cancer Institute
-
Contact:
- Josette Klaus
- Phone Number: 785-623-5761
-
Kansas City, Kansas, United States, 66112
- Recruiting
- KCCC West
-
Contact:
- Kristina Sharpe-Pringle
- Phone Number: 913-328-3206
-
Overland Park, Kansas, United States, 66215
- Recruiting
- Overland Park Regional Medical Center
-
Contact:
- Amy Nelson
- Phone Number: 913-498-7892
-
Overland Park, Kansas, United States, 66210
- Recruiting
- KCCC Overland Park
-
Contact:
- Christy Kuechler
- Phone Number: 9132340459
-
Salina, Kansas, United States, 67401
- Recruiting
- Salina Regional Health Center - Tammy Walker Cancer Center
-
Contact:
- Melanie Leepers, RN, MBA
- Phone Number: 785-452-7038
-
Westwood, Kansas, United States, 66205
- Recruiting
- The University of Kansas Cancer Center
-
Contact:
- Joshua M Staley
- Phone Number: (913) 588-8548
- Email: jstaley2@kumc.edu
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- Recruiting
- Research Medical Center
-
Contact:
- Jennifer Feeback
- Phone Number: 8162764000
-
Kansas City, Missouri, United States, 64131
- Recruiting
- KCCC South
-
Contact:
- Adrienne Harris-Connell
- Phone Number: 816-823-6640
-
Kansas City, Missouri, United States, 64154
- Recruiting
- KCCC - North
-
Contact:
- Nicole Jenci
- Phone Number: 816-584-4879
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Universtiy Health
-
Contact:
- Nikki Malomo
- Phone Number: 8164044093
-
Lee's Summit, Missouri, United States, 64064
- Recruiting
- KCCC Lee's Summit
-
Contact:
- Jan Ward
- Phone Number: 816-350-5825
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria include:
Triple Negative Breast Cancer
- ER/PR <10% and HER negative per current ASCO/CAP guidelines
- Stages I-IV
- Any age at diagnosis
- Patient must be within 5 years of diagnosis
- Eligible regardless of genetic testing status
- Genetic testing recommended for patients meeting NCCN and Medicare guidelines
AND/OR
Germline mutation Carriers
- Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer
- Healthy patients harboring mutations also eligible
- There is no time limit from the time of diagnosis of cancer and enrollment.
- Eligible regardless of personal history of cancer
Exclusion Criteria include:
Triple Negative Breast Cancer -Patient is not within five years of diagnosis
Germline mutation Carriers:
-Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Triple Negative Breast Cancer patients
No intervention
|
|
Germline HBOC Mutation Carriers
No intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC
Time Frame: 5 years
|
5 years
|
|
. Predictors of response to neo/adjuvant chemotherapy in patients with TNBC
Time Frame: 5 years
|
5 years
|
|
Long term Disease free and overall survival rates in TNBC patients treated with different systemic therapies
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Priyanka Sharma, MD, University of Kansas Medical Center
Publications and helpful links
General Publications
- Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.
- Connor CS, Kimler BF, Mammen JM, McGinness MK, Wagner JL, Alsop SM, Ward C, Fabian CJ, Khan QJ, Sharma P. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. J Surg Oncol. 2015 Feb;111(2):198-202. doi: 10.1002/jso.23790. Epub 2014 Sep 29.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genetic Diseases, Inborn
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Skin Diseases
- Breast Diseases
- Neoplastic Syndromes, Hereditary
- Ovarian Neoplasms
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Hereditary Breast and Ovarian Cancer Syndrome
Other Study ID Numbers
Other Study ID Numbers
- KUMC 12614
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.